DDX5 plays a proliferative or oncogenic role in cancer through the coactivation of Androgen Receptor (AR) [85], Runx2 [86] and the p50 subunit of NF-κB [87], and upregulation of cyclin D1 and c-Myc consistent with β-catenin activation [88,89] as well as genes necessary for DNA replication. Here, AR is linked to cancer.